Cutaneous thrombogenic vasculopathy associated with bevacizumab therapy

Dermatology Online Journal

Volumn 20, Issue 6, 2014, Pages

  Kiuru, Maija ^a   Schwartz, Mark ^b   Magro, Cynthia ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Bevacizumab; Cutaneous side effect; Thrombosis; Vascular endothelial growth factor; Vasculopathy

Indexed keywords

BEVACIZUMAB; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

AGED; ANTAGONISTS AND INHIBITORS; CASE REPORT; CHEMICALLY INDUCED; DRUG ERUPTIONS; GLIOBLASTOMA; HUMAN; MALE; PATHOLOGY; SKIN ULCER; THROMBOSIS;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG ERUPTIONS; GLIOBLASTOMA; HUMANS; MALE; SKIN ULCER; THROMBOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84903533757     PISSN: 10872108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003 Jul;349(5):427-434. [PMID 12890841]
2. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 Jun;350(23):2335-2342. [PMID 15175435]
3. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004 Jun;22(11):2184-2191. [PMID 15169807]
4. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007 Dec;357(26):2666-2676. [PMID 18160686]
5. Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004 May;3(5):391-400. [PMID 15136787]
6. Tewari KS, Sill MW, Long HJ, 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014 Feb;370(8):734-743. [PMID 24552320]
7. Veritti D, Lanzetta P. Triple therapy for anti-vascular endothelial growth factor nonresponders in neovascular age-related macular degeneration: impact of different photodynamic therapy parameters. Ophthalmologica. 2013 230(3):131-137. [PMID 23948986]
8. Saif MW. Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike? Cancer Manag Res. 2013 5103-115. [PMID 23807861]
9. Keefe D, Bowen J, Gibson R, et al. Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. Oncologist. 2011 16(4):432-444. [PMID 21441297]
10. Schutz FA, Je Y, Azzi GR, et al. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol. 2011 Jun;22(6):1404-1412. [PMID 21115602]
11. Donadon M, Vauthey JN, Loyer EM, et al. Portal thrombosis and steatosis after preoperative chemotherapy with FOLFIRIbevacizumab for colorectal liver metastases. World J Gastroenterol. 2006 Oct;12(40):6556-6558. [PMID 17072991]
12. Verschraegen CF, Czok S, Muller CY, et al. Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum-and taxane-resistant ovarian cancer. Ann Oncol. 2012 Dec;23(12):3104-3110. [PMID 22851407]
13. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008 Mar;358(11):1129-1136. [PMID 18337603]
14. Hurwitz HI, Saltz LB, Van Cutsem E, et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol. 2011 May;29(13):1757-1764. [PMID 21422411]
15. Frangie C, Lefaucheur C, Medioni J, et al. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol. 2007 Feb;8(2):177-178. [PMID 17267332]
16. Furuyama H, Fuji H, Okumura S, et al. [A case of recurrent colon cancer developed thrombosis in superior mesenteric vein after chemotherapy]. Gan To Kagaku Ryoho. 2013 May;40(5):659-661. [PMID 23863595]
17. Uy AL, Simper NB, Champeaux AL, et al. Progressive bevacizumab-associated renal thrombotic microangiopathy. Clinical Kidney Journal. 2009 2(1):36-39. [PMID
18. Togashi Y, Kim YH, Masago K, et al. Pulmonary embolism due to internal jugular vein thrombosis in a patient with nonsmall cell lung cancer receiving bevacizumab. Int J Clin Oncol. 2011 Aug;16(4):444-446. [PMID 21116671]
19. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007 Jun;96(12):1788-1795. [PMID 17519900]
20. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer. 2007 Jun;7(6):475-485. [PMID 17522716]